ERBB2 and breast cancer: Thus, Loibl and coworkers reached the conclusion that PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer through the pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab [294].